Subcutaneous delivery of hyaluronidase may boost effectiveness of cancer immunotherapy

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
The American Journal of Managed Care

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor ...

Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial 1,3 Opdivo and Opdivo ...
Seeking Alpha

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Benzinga.com

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis

The FDA has approved Argenx SE's (NASDAQ:ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult ...
Healio

Keep hyaluronidase on hand to address injection filler complications

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — Hypersensitivity reactions to injection fillers are rare and unpredictable, but when they occur, ...
MedPage Today

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...
ascopubs.org

Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 ...

A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer. This is an ASCO Meeting Abstract from the ...
Business Wire

Huonslab Strengthens HyDIFFUZE™ (Recombinant Human Hyaluronidase PH20) Intellectual Property with Completion of US and EU Examination Request Under PCT Application

PANGYO, South Korea--(BUSINESS WIRE)--Huonslab, Co. Ltd. S. Korea, a subsidiary of Huons Global (KOSDAQ:084110) and a global leader in recombinant human hyaluronidase-based biologics Sub-Q delivery, ...
Medscape

Hyaluronidase Speeds Up Insulin Absorption From Skin

October 9, 2012 (Berlin, Germany) — In a randomized, double-blind, comparator-controlled, 2-way crossover trial, 2 rapid-acting insulin analogs (lispro or aspart) formulated with recombinant human ...